Association between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH) in Amara city, Iraq


Background: Benign prostatic hyperplasia (BPH) is most common in aging men and causes actual adverse effects on health. Recently the researches have suggested that metabolic syndrome (MetS) individuals’ may be exposure to development of benign prostatic hyperplasia (BPH), this study aimed to evaluated the association between BPH and MetS. Methods: 66 men with BPH (43 without MetS and 23 with MetS) and 30 healthy individuals (as a control group) were included in this study. Sex hormones: Testosterone (T), Estradiol II (E2), Prolactin (PRL), luteinizing hormone (LH), Follicle stimulating hormone (FSH), and lipid profile were all evaluated. Results: There were significant decreasing (p<0.01) in T and E2 level in BPH patients compared to control group, while DHT level had significant increase (p<0.01) in BPH patients compared to control group. No significant differences were found in T, E2, PRL, LH, FSH between BPH with MetS and without MetS except level of DHT had recorded significantly increase (p<0.01) in BPH with MetS compared to without MetS. In term of lipid profile, TC, TG, LDL, VLDL were no significant differences between the BPH with MetS and without MetS, while HDL level revealed significantly decrease (p>0.05) in BPH with MetS compared to without MetS. Conclusions: Our study confirmed on most the association between BPH and MetS related change in the sex hormones (DHT) and metabolic derangement in lipid profile.


  • Abdollah F, Briganti A, Suardi N, Castiglione F, Gallina A, Capitanio U, Montorsi F (2011) Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean journal of urology 52(8): 507-516.
  • Allain C, Poon L, Chan C, Richmond W, Fu P (1974) Enzymatic colorimetric method for cholesterol estimation .Clin. Chem 20: 470-475.
  • Al-Rawi KM (2000) Introduction to statistical. Books house for printing and spreading. Al-Mosul University, Iraq. Pp. 488.
  • Al-Saadi E (2013) Study of some biochemical and immunological parameters in Iraqi benign prostatic hyperplasia and lower urinary tract symptoms patients. Kerbala J. of Pharm. Sci 5: 24-33.
  • Antunes AA, Araújo LH, Nakano E, Muracca E, Srougi M (2014) Obesity may influence the relationship between sex hormones and lower urinary tract symptoms. Int Braz J Urol 40: 240–6.
  • Aruna S, John W (2012) Benign prostatic hyperplasia and lower urinary tract symptoms. N. Engl. J. Med 367: 248-57.
  • Chia-Chu L, Shu-Pin H, Wei-Ming L, Chil-Jye W, Yii-Her C, Ching-Chia L, et al. ( 2007) Relationship between serum testosterone and measure of benign prostatic hyperplasia in aging men. Urology 70: 677-680.
  • Corona G, Vignozzi L, Rastrelli G, Lotti F (2014) Benign prostatic hyperplasia: A new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int. J. Endocrinol. Vol. 2014, Article ID 329456, 14P. Hindawi publishing corporation.
  • Da Silva M, De Souza DB. (2019) Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Research and reports in urology 11: 1–8.
  • De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK (2012).The correlation between metabolic syndrome and prostatic diseases. Eur. Urol 61: 560–570.
  • Doulabi S, Kavoussi H, Hashemian I, Taheriniya A (2013) Effect of finasteride on lipid profile in individuals with androgenetic alopecia. Afri. J. Pharm. Pharmacol 7(6): 315-317.
  • Ejike CE and Ezeanyika LU (2010) Hormonal induction of benign prostatic hyperplasia in rats: effects on serum macromolecular metabolism. Int J Curr Res 6(7): 065-067.
  • Flelih H, Wajeeh Y, Saddam H (2014). Evaluate the level of oxidative stress markers and lipid profile in patients with benign prostate hypertrophy in Al-Khadhmyah Teaching Hospital. al-Kindy College Medical Journal 10(1): 23-26.
  • Foram V, Pooja K, R Ram V, Dave PN (2019) Sex Determination in Papaya: A mini review. Progress in Chemical and Biochemical Research 2(4): 228-234.
  • Friedwald W, Levy R, Fredickson D (1972) Estimation of the concentration of LDL cholesterol in plasma ,without use of the preparative ultracentrifuge. Clin. Chem 18(6): 499-502.
  • Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, et al. (2015) Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU international 115(1): 24–31.
  • Gacci M, Sebastianelli A, Salvi M (2018) Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Chapter 5 - Metabolic Syndrome and LUTS/BPH. University of Florence, Florence, Italy: 89-111.
  • Hammarsten J, Högstedt B, Holthuis N, Mellström D (1998) Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1: 157-62.
  • Hernandez M, Soto-Cid A, Rojas F, Pascual L, Aranda-Abreu G, Toledo R, Manzo J (2006) Prostate response to prolactin in sexually active male rats. Rep. Biol. Endocrinol 4(1): 28.‏
  • Herrera-Covarrubias D, Coria-Avila G, Xicotencatl, C, Fernandez-Pomares C, Manzo J, Aranda-Abreu G, Hernandez M (2015) Long-term administration of prolactin or testosterone induced similar precancerous prostate lesions in rats. Exp. Oncol 37(1): 13-18.
  • Ho CK, Habib FK (2011) Estrogen and androgen signaling in the pathogenesis of BPH. Nature Reviews Urology 8: 29–41.
  • Khaleel F, Ihsan A, Ghazi N (2013) Estimation of testosterone, estradiol and some markers in sera of Iraqi with Benign Prostatic Hyperplasia. J. Baghdad Sci 10(4): 1162-1171.
  • Kristal A, Schenk J, Song Y, Arnold K, Neuhouser M, Goodman P, Lin D, Stanczyk F, Thompson I (2008) Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am. J. Epidemiol 168(12): 1416–1424.
  • La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE (2016) Endocrine control of benign prostatic hyperplasia. Andrology 4(3): 404-411
  • Lanini A, Yodo S, Sulbadana LP, Syafiuddin I (2019) Model of Dispute Settlement over Natural Resources in Lore Lindu National Park Central Sulawesi, Indonesia. Journal of Environmental Treatment Techniques 7(4): 595-600.
  • Litman H, Bhasin S, O’Leary M, Link C, McKinlay J (2007) An investigation of the relationship between sex‐steroid levels and urological symptoms: Results from the Boston Area Community Health survey. BJU 100(2): 321-326.‏
  • Lopes-Virella M, Stone P, Ellis S (1977) Cholesterol determination in high density lipoprotein separated by three different methods. Clin. Chem 23(5): 882-884.
  • McGrown C, Birerdinc A, Younossi Z (2014) Adipose tissue as an endocrine organ. Clin Liver Dis 18: 41-58.
  • Mohammed M, Abduiridha MK, Al-Muiia Himmadi YM (2012) Body mass index, lipid profile, leptin level and their correlation with prostate specific antigen (PSA) in Iraqi patients with Benign Prostatic Hyperplasia (BPH). Kerbala J. Pharm. Sci 4: 18-31.
  • Nakhaei A, Davoodnia A, Nakhaei H (2019) (NH4) 42 [MoVI72MoV60O372 (CH3COO) 30 (H2O) 72] as a Heterogeneous Reusable Catalyst for Organic Reactions: Mini-Review. Journal of Chemical Reviews 1(2. pp. 78-153): 139-153.
  • Nevalainen M, Valve E, Ingleton P, Nurmi M, Martikainen P, Harkonen P (1997) Prolactin and prolactin receptors are expressed and functioning in human prostate. J. Clin. Invest 99(4): 618.‏
  • Parsons JK (2007). Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. The Journal of urology 178(2): 395-401.
  • Parsons JK, Bergstrom J, Barrett‐Connor E (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community‐dwelling men. BJU international 101(3): 313-318.
  • Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, ... Platz EA (2006) Metabolic factors associated with benign prostatic hyperplasia. The Journal of Clinical Endocrinology & Metabolism 91(7): 2562-2568.
  • Patel ND, Parsons JK (2014) Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. J. Urol 30(2): 170-176.
  • Qin-Song Z, Chuan-Liang X, Zhi-Yong L, Hui-Qing W, Bo Y, Wei-Dong Xu H-Q, et al. (2012) Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men. Asian Journal of Andrology 14: 773–777
  • Rahman N, Phonsombat S, Bochinski D, Carrion R, Nunes L, Lue T (2007) An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU. Int 100(3): 658-663.
  • Razumovskaya MI, Larionova AA, Zaitseva NA, et al. (2019) Models of Integrated Interactions Organization in the Field of Environmental Education. Journal of Environmental Treatment Techniques, 7(4): 576-580.
  • Roberts R, Jacobson D, Rhodes T, Klee G, Leiber M, Jacobsen S (2004) Serum sex hormones and measures of benign prostatic hyperplasia. The Prostate 61(2):124–131.
  • Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, ... Platz EA (2007) Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 69(4): 708-713.
  • Rył A, Rotter I, Słojewski M, Jędrzychowska A, Marcinowska Z, Grabowska M, Laszczyńska M (2015) Can metabolic disorders in aging men contribute to prostatic hyperplasia eligible for transurethral resection of the prostate (TURP)?. International journal of environmental research and public health 12(3): 3327-3342.
  • Sahi I, Ramadhan, M, Khadim S (2013) Hormonal disturbances in patients with benign prostate hyperplasia. Bas. J. Surg, March 19:61-67.
  • Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S, Ponholzer A (2009) Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 73: 544–8.
  • Tewari R, Chhabra M, Natu S, Goel A, Dalela D, Goel M, Rajender S (2014) Significant association of metabolic indices, lipid profile, and androgen levels with prostate cancer. Asian Pac. J. Cancer Prev 15(22): 9841-9846.
  • Tewari R, Prabhat P, Natu SM, Dalela D, Goel A, Goel M, Tandon P (2011) Association of benign prostatic hyperplasia (BPH) with the metabolic syndrome (MS) and its components–’a growing dilemma’. J. of Men’s Health 8(1): 66-71.‏
  • Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat. Rev. Urol 13: 108–119.
  • Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M (2014) Benign prostatic hyperplasia: a new metabolic disease?. Journal of endocrinological investigation 37(4): 313-322.
  • Vikram A, Jena G (2012) Diet-induced hyperinsulinemia accelerates growth of human androgen independent PC-3 cells. Nutrition and cancer 64(1): 121-127.
  • Wang J, Fu Y, Kang D (2016) Associations between metabolic syndrome and characteristics of benign prostatic hyperplasia. Medicine 19: 1-10.
  • Wheeler MJ (2006) Measurement of androgens. Methods Mol. Biol 324: 197-211. Review.
  • Yu W, Hong P, Wei‑Ming W, Ding X, Liang Z, Zheng‑Qin G, et al. (2016) A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection. Asian Journal of Andrology 18: 1–4.
  • Zhao SC, Xia M, Tang JC, Yan Y (2016). Associations between metabolic syndrome and clinical benign prostatic hyperplasia in a northern urban Han Chinese population: A prospective cohort study. Scientific reports 6: 33933.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.